Google Life Sciences, better known as Verily, are trying their hands at bioelectronic medicine. With help from GlaxoSmithKline (GSK), they think they could treat diseases such as diabetes #todaymagic
The news couldn’t have come at a better time, since diabetes is affecting 422 million people worldwide. Almost every cell of our body is directly or indirectly controlled by signals send by the nervous system to communicate information. Bioelectronic medicine technologies can record, stimulate, and block neural signaling through small implants that alter the impulses with their own, electrical signals. GSK’ pharmaceutical experience with Verily’s expertise in small, low power electronics is a great premise for impressive achievements in this field.
Galvani Bioelectronics will be the company under which the medicines will be developed. There’s only a team of 30 scientists, engineers and clinicians right now that are focused on bringing together technologies and knowledge from both companies and other R&D firms, too. After making progress in the area of diabetes, the team will research and hopefully develop a cure for asthma and arthritis as well.